Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 373-383

  Zhong, Yan Jun ^a,b   Shao, Li Hua ^a,b   Li, Yan ^a,b  

^a WUHAN UNIVERSITY   (China)

^b Hubei Cancer Clinical Study Center   (China)

Author keywords

Cancer chemotherapy; Cathepsin B; Doxorubicin; Prodrugs; Targeted therapy

Indexed keywords

BETA GLUCURONIDASE; CARBOXYLESTERASE; CATHEPSIN B; DIPEPTIDE; DOXORUBICIN; GALECTIN 3; OLIGOPEPTIDE; PROTEINASE; TETRAPEPTIDE;

ANTINEOPLASTIC ACTIVITY; CANCER INVASION; CANCER THERAPY; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CATHEPSIN B; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; PRODRUGS;

EID: 84873664097     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1754     Document Type: Review

References (106)

1. Gianni L, Grasselli G, Cresta S, Locatelli A, Vigano L and Minotti G: Anthracyclines. Cancer Chemother Biol Response Modif 21: 29-40, 2003.
2. Abu Ajaj K, Graeser R, Fichtner I and Kratz F: In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64: 413-418, 2009.
3. Ogura M: Adriamycin (doxorubicin). Gan To Kagaku Ryoho 28: 1331-1338, 2001 (In Japanese).
4. Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, Sanchez-Rovira P and Ramirez-Tortosa MC: New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem Toxicol 48: 1425 1438, 2010.
5. Herman EH, Ferrans VJ, Jordan W and Ardalan B: Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31: 85-97, 1981.
6. Wexler LH, Andrich MP, Venzon D, et al: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14: 362-372, 1996.
7. Lipshultz SE: Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 14: 328-331, 1996.
8. Cattel L, Ceruti M and Dosio F: From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89: 237-249, 2003.
9. Li J, Wu C, Dai Y, Zhang R, Wang X, Fu D and Chen B: Doxorubicin-CdS nanoparticles: a potential anticancer agent for enhancing the drug uptake of cancer cells. J Nanosci Nanotechnol 7: 435-439, 2007.
10. Ascensao A, Lumini-Oliveira J, Machado NG, et al: Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opening in doxorubicin-treated rats. Clin Sci 120: 37-49, 2011.
11. Yeung TK, Hopewell JW, Simmonds RH, et al: Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat. Cancer Chemother Pharmacol 29: 105-111, 1991.
12. Shao LH, Liu SP, Hou JX, et al: Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer 118: 2986-2996, 2011.
13. Kratz F, Warnecke A, Schmid B, Chung DE and Gitzel M: Prodrugs of anthracyclines in cancer chemotherapy. Curr Med Chem 13: 477-523, 2006.
14. Muller MB, Keck ME, Binder EB, et al: ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary- adrenocortical system: implications for affective disorder. Neuropsychopharmacology 28: 1991-1999, 2003.
15. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
16. Lu Y, Yang J and Sega E: Issues related to targeted delivery of proteins and peptides. AAPS J 8: E466-E478, 2006.
17. Juillerat-Jeanneret L and Schmitt F: Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med Res Rev 27: 574-590, 2007.
18. Calderon M, Graeser R, Kratz F and Haag R: Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol. Bioorg Med Chem Lett 19: 3725-3728, 2009.
19. Haag R and Kratz F: Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 45: 1198-1215, 2006.
20. Duncan R: Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688-701, 2006.
21. Vicent MJ, Dieudonne L, Carbajo RJ and Pineda-Lucena A: Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv 5: 593-614, 2008.
22. Kiick KL: Materials science. Polymer therapeutics. Science 317: 1182-1183, 2007.
23. Schilsky RL: Pharmacology and clinical status of capecitabine. Oncology 14: 1297-1306; discussion 1309-1311, 2000.
24. Basu SK: Receptor-mediated endocytosis of macromolecular conjugates in selective drug delivery. Biochem Pharmacol 40: 1941-1946, 1990.
25. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T and Maeda H: Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89: 307-314, 1998.
26. Shiah JJ, Sun Y, Peterson CM and Kopecek J: Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release 61: 145-157, 1999.
27. Bogdanov A Jr, Wright SC, Marecos EM, Bogdanova A, Martin C, Petherick P and Weissleder R: A long-circulating co-polymer in 'passive targeting' to solid tumors. J Drug Target 4: 321-330, 1997.
28. Kopecek J, Sprincl L and Lim D: New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. J Biomed Mater Res 7: 179-191, 1973.
29. Sprincl L, Exner J, Sterba O and Kopecek J: New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl) methacrylamide] in a test organism. J Biomed Mater Res 10: 953-963, 1976.
30. Etrych T, Kovar L, Strohalm J, Chytil P, Rihova B and Ulbrich K: Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy. J Control Release 154: 241-248, 2011.
31. Satchi-Fainaro R, Puder M, Davies JW, et al: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10: 255-261, 2004.
32. Satchi-Fainaro R, Mamluk R, Wang L, et al: Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7: 251-261, 2005.
33. Kasuya Y, Lu ZR, Kopeckova P, Minko T, Tabibi SE and Kopecek J: Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates. J Control Release 74: 203-211, 2001.
34. Nishiyama N, Nori A, Malugin A, Kasuya Y, Kopeckova P and Kopecek J: Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res 63: 7876-7882, 2003.
35. Etrych T, Mrkvan T, Rihova B and Ulbrich K: Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. J Control Release 122: 31-38, 2007.
36. Vasey PA, Kaye SB, Morrison R, et al: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5: 83-94, 1999.
37. Bilim V: Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr Opin Mol Ther 5: 326-330, 2003.
38. Seymour LW, Ferry DR, Kerr DJ, et al: Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34: 1629-1636, 2009.
39. Thomson AH, Vasey PA, Murray LS, Cassidy J, Fraier D, Frigerio E and Twelves C: Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer 81: 99-107, 1999.
40. Julyan PJ, Seymour LW, Ferry DR, et al: Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release 57: 281-290, 1999.
41. Seymour LW, Ferry DR, Anderson D, et al: Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676, 2002.
42. Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J and Duncan R: N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer 63: 859-866, 1991.
43. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al: Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315-323, 2001.
44. Rice JR, Gerberich JL, Nowotnik DP and Howell SB: Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12: 2248-2254, 2006.
45. Nowotnik DP and Cvitkovic E: ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev 61: 1214-1219, 2009.
46. Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH and Schellens JH: Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol 60: 523-533, 2007.
47. Van der Schoot SC, Nuijen B, Sood P, Thurmond KB II, Stewart DR, Rice JR and Beijnen JH: Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. Pharmazie 61: 835-844, 2006.
48. Sood P, Thurmond KB II, Jacob JE, Waller LK, Silva GO, Stewart DR and Nowotnik DP: Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug Chem 17: 1270-1279, 2006.
49. Rademaker-Lakhai JM, Terret C, Howell SB, et al: A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10: 3386-3395, 2004.
50. Tibben MM, Rademaker-Lakhai JM, Rice JR, Stewart DR, Schellens JH and Beijnen JH: Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl) methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Anal Bioanal Chem 373: 233-236, 2002.
51. Lin X, Zhang Q, Rice JR, Stewart DR, Nowotnik DP and Howell SB: Improved targeting of platinum chemotherapeutics. The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer 40: 291-297, 2004.
52. Podgorski I and Sloane BF: Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 70: 263-276, 2003.
53. Calkins CC, Sameni M, Koblinski J, Sloane BF and Moin K: Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy. J Histochem Cytochem 46: 745-751, 1998.
54. Kovar M, Strohalm J, Etrych T, Ulbrich K and Rihova B: Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem 13: 206-215, 2002.
55. Thanou M and Duncan R: Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs 4: 701-709, 2003.
56. Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 1477: 215-230, 2000.
57. Kratz F, Muller IA, Ryppa C and Warnecke A: Prodrug strategies in anticancer chemotherapy. ChemMedChem 3: 20-53, 2008.
58. Trouet A, Masquelier M, Baurain R and Deprez-De Campeneere D: A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci USA 79: 626-629, 1982.
59. Omelyanenko V, Kopeckova P, Gentry C and Kopecek J: Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization and subcellular fate. J Control Release 53: 25-37, 1998.
60. Carl PL, Chakravarty PK and Katzenellenbogen JA: A novel connector linkage applicable in prodrug design. J Med Chem 24: 479-480, 1981.
61. Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J and Duncan R: Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer 70: 636-641, 1994.
62. Duncan R, Kopeckova P, Strohalm J, Hume IC, Lloyd JB and Kopecek J: Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer 57: 147-156, 1988.
63. Duncan R, Kopeckova-Rejmanova P, Strohalm J, et al: Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 55: 165-174, 1987.
64. Hopewel JW, Duncan R, Wilding D and Chakrabarti K: Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol 20: 461-470, 2001.
65. Minko T, Kopeckova P, Pozharov V and Kopecek J: HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54: 223-233, 1998.
66. Minko T, Kopeckova P and Kopecek J: Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release 59: 133-148, 1999.
67. Tijerina M, Fowers KD, Kopeckova P and Kopecek J: Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials 21: 2203-2210, 2000.
68. Minko T, Kopeckova P and Kopecek J: Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 86: 108-117, 2000.
69. Duncan R: Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3: 175-210, 1992.
70. Kovar L, Strohalm J, Chytil P, et al: The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Bioconjug Chem 18: 894-902, 2007.
71. Satchi R, Connors TA and Duncan R: PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br J Cancer 85: 1070-1076, 2001.
72. Paul A, Vicent MJ and Duncan R: Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates. Biomacromolecules 8: 1573-1579, 2007.
73. Pimm MV, Perkins AC, Strohalm J, Ulbrich K and Duncan R: Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J Drug Target 3: 385-390, 1996.
74. Duncan R, Seymour LC, Scarlett L, Lloyd JB, Rejmanova P and Kopecek J: Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta 880: 62-71, 1986.
75. Virgolini I, Muller C, Klepetko W, Angelberger P, Bergmann H, O'Grady J and Sinzinger H: Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. Br J Cancer 61: 937-941, 1990.
76. Schlepper-Schafer J, Hulsmann D, Djovkar A, Meyer HE, Herbertz L, Kolb H and Kolb-Bachofen V: Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp Cell Res 165: 494-506, 1986.
77. Shiah JG, Dvorak M, Kopeckova P, Sun Y, Peterson CM and Kopecek J: Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur J Cancer 37: 131-139, 2001.
78. Rihova B, Bilej M, Vetvicka V, Ulbrich K, Strohalm J, Kopecek J and Duncan R: Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10: 335-342, 1989.
79. Omelyanenko V, Kopeckova P, Gentry C, Shiah JG and Kopecek J: HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 3: 357-373, 1996.
80. Omelyanenko V, Gentry C, Kopeckova P and Kopecek J: HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 75: 600-608, 1998.
81. Kunath K, Kopeckova P, Minko T and Kopecek J: HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur J Pharm Biopharm 49: 11-15, 2000.
82. Jensen KD, Kopeckova P, Bridge JH and Kopecek J: The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci 3: E32, 2001.
83. David A, Kopeckova P, Kopecek J and Rubinstein A: The role of galactose, lactose and galactose valency in the biorecognition of N-(2-hydroxypropyl) methacrylamide copolymers by human colon adenocarcinoma cells. Pharm Res 19: 1114-1122, 2002.
84. David A, Kopeckova P, Rubinstein A and Kopecek J: Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem 12: 890-899, 2001.
85. Irimura T, Matsushita Y, Sutton RC, et al: Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 51: 387-393, 1991.
86. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P and Raz A: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115: 287-296, 1998.
87. Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ and Lotan R: Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55: 2191-2199, 1995.
88. Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A and Mercurio AM: Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90: 3466-3470, 1993.
89. Castronovo V, Campo E, van den Brule FA, et al: Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84: 1161-1169, 1992.
90. David A, Kopeckova P, Minko T, Rubinstein A and Kopecek J: Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer 40: 148-157, 2004.
91. Etrych T, Strohalm J, Chytil P, Cernoch P, Starovoytova L, Pechar M and Ulbrich K: Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. Eur J Pharm Sci 42: 527-539, 2011.
92. Dvorak M, Kopeckova P and Kopecek J: High-molecular weight HPMA copolymer-adriamycin conjugates. J Control Release 60: 321-332, 1999.
93. Etrych T, Jelinkova M, Rihova B and Ulbrich K: New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release 73: 89-102, 2001.
94. Schmid B, Chung DE, Warnecke A, Fichtner I and Kratz F: Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 18: 702-716, 2007.
95. Kratz F, Warnecke A, Scheuermann K, et al: Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 45: 5523-5533, 2002.
96. Warnecke A and Kratz F: Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjug Chem 14: 377-387, 2003.
97. Kratz F and Beyer U: Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv 5: 281-299, 1998.
98. Elzoghby AO, Samy WM and Elgindy NA: Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157: 168-182, 2012.
99. Kratz F: Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171-183, 2008.
100. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Kratz F and Walker UA: The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 120: 927-934, 2007.
101. Unger C, Haring B, Medinger M, Drevs J, Steinbild S, Kratz F and Mross K: Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 13: 4858-4866, 2007.
102. Dubowchik GM and Firestone RA: Cathepsin B sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 8: 3341-3346, 1998.
103. Dubowchik GM, Mosure K, Knipe JO and Firestone RA: Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett 8: 3347-3352, 1998.
104. Dubowchik GM, Firestone RA, Padilla L, et al: Cathepsin B labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13: 855-869, 2002.
105. Calderón M, Quadir MA, Strumia M and Haag R: Functional dendritic polymer architectures as stimuli-responsive nanocarriers. Biochimie 92: 1242-1251, 2010.
106. De Groot FM, Broxterman HJ, Adams HP, et al: Design, synthesis and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol Cancer Ther 1: 901-911, 2002.